All In Biotech

Drug Trial Radar · NCT04096326

AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

A Phase 2b Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of AGN-151586 in Participants With Moderate to Severe Glabellar Lines

Last checked: Nov 20, 2026Latest source record: Jul 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 198 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

198

Actual

Start

Sep 26, 2019

Primary completion

Sep 9, 2020

Study completion Sep 9, 2020

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Sep 19, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of AGN-151586 over a range of doses for the treatment of moderate to severe glabellar lines (GL).

Conditions

  • Glabellar Lines

Interventions

  • AGN-151586Drug

    AGN-151586 solution for injection.

  • PlaceboDrug

    Placebo solution for injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With ≥ 2-grade Improvement From Baseline on the FWS According to Investigator's Assessment at Any Postintervention Timepoint Through Day 7Time frame: Baseline (Day 1) through Day 7
  2. Number of Participants Who Experience One or More Treatment Emergent Adverse Events (TEAEs)Time frame: From first dose of study drug until the end of study (up to 42 days)
  3. Number of Participants With Potentially Clinically Significant Laboratory Parameters Post InterventionTime frame: From first dose of study drug until the end of study (up to 42 days)
  4. Number of Participants With Potentially Clinically Significant Vital Signs Post InterventionTime frame: From first dose of study drug until the end of study (up to 42 days)
  5. Number of Participants With Potentially Clinically Significant Electrocardiogram Findings Post InterventionTime frame: From first dose of study drug until the end of study (up to 42 days)
  6. Number of Participants With Anti-drug Antibodies (ADAs)Time frame: Up to Day 42

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Center for Dermatology Clinical Research /ID# 237798

    Fremont, California

  • Ava T. Shamban MD - Santa Monica. /ID# 235353

    Santa Monica, California

  • Skin and Cancer Associates, LLP /ID# 236231

    Miami, Florida

  • Laser and Skin Surgery Center of Indiana /ID# 236588

    Indianapolis, Indiana

  • Wilmington Dermatology Center /ID# 237055

    Wilmington, North Carolina

  • Kgl, Llc /Id# 234798

    Newtown Square, Pennsylvania

  • DermResearch Inc. /ID# 234483

    Austin, Texas

  • Austin Institute for Clinical Research at SBA Dermatology /ID# 236646

    Houston, Texas

  • Austin Institute for Clinical Research /ID# 237135

    Pflugerville, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.